Prevalence, control, and treatment of diabetes, hypertension, and high cholesterol in the Amish

Shisi He, Kathleen A Ryan, Elizabeth A Streeten, Patrick F McArdle, Melanie Daue, Donna Trubiano, Yvonne Rohrer, Patrick Donnelly, Maryann Drokelet, Sylvia Newcomer, Susan Shaub, Nancy Weitzel, Alan R Shuldiner, Toni I Pollin, Braxton D Mitchell

ABSTRACT

Background The burden of diabetes and cardiovascular risk is not uniform across the USA, with much of this disparity tracking differences in socioeconomic status, cultural practices and lifestyle. To further evaluate disparities in these disorders, we assessed the prevalence of diabetes, hypertension, and hypercholesteroleraemia in an Old Order Amish community that is characterized by distinctive sociocultural practices that include a very cohesive social structure and limited use of modern technologies and medications. We compared prevalence of these conditions with that of the overall US population.

Method We performed a community-wide survey in 5377 Amish individuals aged 18 years and older from the Lancaster County, Pennsylvania, Amish settlement that included a basic physical examination and fasting blood draw during the period 2010–2018. We then compared the prevalence of diabetes, hypertension, and high cholesterol, defined using standard criteria, between the Amish and the European Caucasian subsample of the 2013–2014 US National Health and Nutrition Examination Survey (NHANES).

Results Prevalence rates for diabetes, hypertension and hypercholesterolaemia were 3.3%, 12.7%, and 26.2% in the Amish compared with 13.2%, 37.8% and 35.7% in NHANES (p<0.001 for all). Among individuals with these disorders, Amish were less likely to be aware that they were affected, and among those aware, were less likely to be treated with a medication for their disorder.

Conclusion There is substantially lower prevalence of diabetes, hypertension and hypercholesterolaemia in the Amish compared with non-Amish Caucasians in the USA. Possible factors contributing to this disparity include higher physical activity levels in the Amish or other protective sociocultural factors. A greater understanding of which could inform risk reduction interventions for these chronic diseases.

INTRODUCTION

Heart disease is the leading cause of death in the USA, and by the year 2035, over 130 million adults in the US population are projected to have some form of cardiovascular disease (CVD) with total costs projected to reach $1.1 trillion.1 Among the major risk factors for CVD are hypertension, hypercholesterolaemia, and diabetes. In 2005, it was estimated that hypertension alone was responsible for 45% of all cardiovascular deaths.2 Deaths due to CVD in the USA increased steadily in the 20th century until about 1980, after which point CVD-attributable deaths have slowly decreased.1 Alarming, however, this rate has leveled off beginning in about 2010. Of particular concern is that the prevalence of the major CVD risk factors continues to be high. In fact, the prevalence of hypertension among US adults increased between 1988 and 1999 to a rate of 28.5%, although this rate has not changed through 2012.3 4 Diabetes...
prevalence among US adults has increased steadily from 1988 to 2012, at which point the population prevalence was estimated at 14.3%.\textsuperscript{5} In contrast, the proportion of individuals with high total and low-density lipoprotein (LDL) cholesterol levels have decreased over the past 30 years, although this decrease has been accompanied by an increase in use of cholesterol-lowering medications.\textsuperscript{6–8}

The burden of CVD and its risk factors is not uniform across the country, and comparisons across subpopulations can be informative in highlighting health disparities and providing insights into disease risk. One such subpopulation is the Old Order Amish (OOA), a rural population isolate with distinctive sociocultural practices that includes a very cohesive social structure and limited use of modern technologies. The oldest Amish settlement in the USA is in Lancaster County, Pennsylvania, which is currently home to ~38,000 Amish. Through community surveys of CVD and its risk factors, we have estimated the prevalence of the major CVD risk factors. In this paper, we report the prevalence and control of diabetes, hypertension, and high cholesterol in the Amish, contrasting these estimates with those obtained from the US National Health and Nutrition Examination Survey (NHANES).

**RESEARCH DESIGN AND METHODS**

The Lancaster County Amish

The OOA of Lancaster County, Pennsylvania, are a population isolate. The OOA first immigrated to America from Central Europe, primarily present-day Switzerland, in the early 1700s. The Lancaster area community remains the largest of the Amish settlements in the USA, with an estimated size of ~38,000,\textsuperscript{9} virtually all descendants of the original founders.\textsuperscript{10} The present report is based on subjects participating in the Amish Wellness Study, a community survey carried out to assess cardiovascular and metabolic health, disseminate this information to study participants, and evaluate associations of genetic and other risk factors with common diseases and related traits. These analyses are limited to 5377 adult participants of the Amish Wellness Study enrolled between its initiation in January 2010 and February 2018.

Recruitment

The Amish community in Lancaster County is divided into church districts, each consisting of up to 50 households. Enrollment into the wellness study was structured around church districts, and data for this report are compiled from subjects in the initial 101 (of a total of 122) church districts. We targeted these initial church districts because of their proximity to our Amish Research Clinic in Lancaster. For each selected church district, our recruitment teams (consisting of a research nurse and Amish liaison) first visited each household and invited the heads of the household to participate. If the head of household agreed, then he or she in turn invited all age-eligible (≥18 years) persons in their household to participate. At this visit, the team obtained informed consent for a clinical exam, administered medical history questionnaires, and scheduled subjects for an appointment.

The study examinations were conducted in the Amish Research Clinic or the Amish Wellness mobile, a refurbished recreation vehicle that includes walk-in space for participant interviews, anthropometry and blood pressure measurements, a blood drawing station, and a centrifuge for blood processing. Blood pressure was measured in triplicate on a sphygmomanometer, and blood pressure was defined as the average of all three readings. Fasting bloods were drawn and sent to Quest Diagnostics (Horsham, Pennsylvania) for measurement of lipids and glucose. Glycosylated hemoglobin (HbA1c) was not added to the Amish protocol until November 2013 and so diabetes was assessed in only 3302 (61.4%) of the Amish subjects with HbA1c, fasting glucose, and medication data.

**Disease definitions**

Disease definitions (diabetes, hypertension, and hypercholesterolemia) were harmonized for these analyses to match those used in the NHANES 2013–2014 cycle. Subjects had diabetes if they were currently taking blood glucose-lowering medications (and had previously been told by a doctor that they had diabetes) or had a fasting blood glucose ≥126 mg/dL or an HbA1c ≥6.5%. All other subjects not meeting these criteria were considered not to have diabetes.

Subjects were considered to have hypertension if they were currently taking blood pressure-lowering medications (and had previously been told by a doctor that they had high blood pressure) or had a systolic blood pressure (SBP) ≥140 mm Hg or a diastolic blood pressure (DBP) ≥90 mm Hg. Blood pressures were measured in 99.9% (5,370/5,377) of Amish subjects and in 93.7% (2408/2571) of NHANES subjects. Blood pressures were calculated by taking the mean of up to three blood pressure readings. Of the subjects with blood pressure data, all Amish and 99.7% of NHANES had more than two blood pressure readings. Subjects reporting that they were currently taking cholesterol-lowering medications or had total cholesterol levels ≥240 mg/dL or LDL cholesterol levels ≥160 mg/dL were considered to have high total cholesterol or high LDL cholesterol, respectively. Forty-nine Amish participants reported a negative history of hypertension, but a review of their current medications indicated that they were currently taking a blood pressure-lowering medication. These subjects were therefore considered to have hypertension. Similarly, 12 Amish subjects reported a negative history of high cholesterol, but a review of their current medications indicated that they were currently taking a cholesterol-lowering medication. These subjects were considered to have high cholesterol. We were unable to review the current medications of NHANES subjects, and therefore all NHANES subjects reporting a negative history of hypertension or high cholesterol were considered to be unaffected...
providing that they met the blood pressure or cholesterol criteria.

We considered persons with diagnosed diabetes, hypertension, or high cholesterol to be ‘aware’ of their disease if they reported that they had previously been told by a doctor that they had diabetes/hypertension or that they had high levels of fat or cholesterol or triglyceride in their blood. We considered persons with diagnosed disease to be treated if they were ‘aware’ of their disease and also reported that they were currently taking a medication for their disease.

**European Caucasians**

We compared diabetes, hypertension, and hypercholesterolemia prevalence in the Amish with that in non-Amish NHANES participants from the 2013–2014 cycle of NHANES. NHANES data are downloaded from https://www.cdc.gov/nchs/nhanes. We used only European Caucasians from NHANES (n=2571) to match the European ancestry of the Amish.

**Statistical analysis**

We compared the frequencies of diabetes, hypertension, and hypercholesterolemia between Amish and NHANES stratified by age group using Poisson regression to calculate the prevalence rate ratio (PRR) using the SAS V.9.4 software. For total cholesterol, we compared Amish and NHANES both in all subjects and after excluding 12.5% of Amish who are carriers of the known APOB R3527Q mutation that is common in the Amish and is a known cause of familial hypercholesterolemia. Among subjects meeting diagnostic criteria for diabetes, hypertension, or hypercholesterolemia, we compared by χ² test the proportion of subjects responding that they had previously been told by a doctor of their disease (ie, were ‘aware’ of their disease), and we compared the proportions of Amish and NHANES subjects currently taking medications for their disease (ie, ‘treated’) among those ‘aware’ of their disease. We did not use NHANES sampling weights in these analyses because we used Caucasians from NHANES only and stratified all analyses by age and sex.

**RESULTS**

This report is based on 5377 subjects recruited into the Amish Wellness Study between 2010 and 2018. The mean household response rate across church districts was 65.6%; that is, ~2/3 of households in each church district had at least one participating family member (range: 20%–93%). The mean age of study participants was 43.7 years (range 18–93), and mean body mass index was 26.7 kg/m² (range: 15.1–68.5). The study participants were 42.6% male (n=2291). The overall prevalence rates for diabetes, hypertension, and hypercholesterolemia were 3.3%, 12.7%, and 35.7%, respectively (table 1). In general, the sex differences in the prevalence of diabetes, hypertension, and high cholesterol observed in the Amish mirrored those seen in NHANES. After adjustment for age and sex, the prevalence rates for diabetes, hypertension, and hypercholesterolemia were significantly higher in NHANES compared with Amish, and these differences persisted with further adjustment for body mass index (table 1).

The prevalence of diabetes in the Amish increased from 0.6% (95% CI 0.3% to 1.0%) to 4.6% (95% CI 3.4% to 6.2%) to 11.7% (95% CI 8.9% to 15.0%) across the three age groups (18–44, 45–64, and 65+ years) (figure 1 and table 2). The corresponding prevalence rates in NHANES were 4.4%, 15.1%, and 24.2%. The age-adjusted and sex-adjusted prevalence of diabetes was 3.3% and 13.1% in the Amish and NHANES, respectively (PRR: 0.34 (95% CI 0.27 to 0.42), p<0.001). Among subjects with diabetes, 11 Amish (representing 10.2% of all Amish subjects with diabetes) and 14 NHANES (representing 4.3% of all NHANES subjects with diabetes) were currently taking insulin and reported an age of diabetes onset before the age of 25 years. Thus, a larger proportion of Amish subjects with diabetes may potentially have type 1 diabetes mellitus (T1DM) compared with NHANES subjects with diabetes. We have previously published that Amish individuals with age of diabetes diagnosis ≤35 years, but not those with age of diabetes diagnosis >35 years, are significantly more likely to be glutamic acid decarboxylase (GAD) antibody positive than Amish individuals without diabetes. However, the overall prevalence of diabetes is much lower in Amish than NHANES, and in terms of population prevalence, Amish were less likely to have potential T1DM (11/3302, or 0.3%) compared with NHANES (14/2444, or 0.6%).

Because HbA1c was not measured in the first 4 years of the wellness study, we assessed the comparability of the 3302 wellness participants with HbA1c values (from November 2013 to January 2018) with the 2067 wellness participants without HbA1c values (January 2010–October 2013). The proportion of subjects who were currently using glucose-lowering medications was virtually identical between the two groups (1.8% vs 1.8%, p=0.83). Similarly, the frequency of diabetes based on medication use and fasting glucose criteria only was also similar between the two groups (2.5% vs 2.7%, p=0.72).

The prevalence of hypertension in the Amish increased from 18% (95% CI 14% to 23%) to 17.6% (95% CI 15.7% to 19.6%) to 46.4% (95% CI 42.8% to 50.0%) in individuals across the three age groups (figure 2 and table 2). The corresponding prevalence rates in NHANES were 11.5%, 43.3%, and 71.8%. The age-sex-adjusted prevalence of hypertension was 12.7% and 37.8% in the Amish and NHANES, respectively (PRR: 0.46 (95% CI 0.42 to 0.51), p<0.0001).

The prevalence of high total and LDL cholesterol was higher in the Amish than in NHANES in the 18–44 years age group (18.2% vs 13.4% for total cholesterol and hypercholesterolemia were 13.2%, 37.8%, and 35.7%, respectively (table 1). In general, the sex differences in the prevalence of diabetes, hypertension, and high cholesterol observed in the Amish mirrored those seen in NHANES. After adjustment for age and sex, the prevalence rates for diabetes, hypertension, and hypercholesterolemia were significantly higher in NHANES compared with Amish, and these differences persisted with further adjustment for body mass index (table 1).
### Table 1  Clinical characteristics of Amish and NHANES subjects (mean±SD or % affected)

|                  | Amish 2010–2018 | NHANES 2013–2014 | Amish versus NHANES* |
|------------------|------------------|------------------|----------------------|
|                  | n=5377 Men, n=2291 Women, n=3086 | n=2571 Men, n=1231 Women, n=1340 | Age-adjusted p value† |
| **Age (years)**  | 43.7 (16.8) | 45.4 (16.4) | 42.5 (16.9) | <0.0001 | 50.0 (19.3) | 49.1 (19.4) | 50.9 (19.2) | 0.02 | <0.0001 |
| Body mass index (kg/m$^2$) | 26.7 (5.0) | 26.3 (4.2) | 27.1 (42.5) | <0.0001 | 29.0 (7.1) | 28.6 (6.3) | 29.3 (7.8) | 0.01 | <0.0001 |
| Fasting glucose (mg/dL) | 85.8 (16.4) | 87.2 (14.9) | 84.7 (17.3) | 0.003 | 106.2 (31.1) | 108.7 (32.8) | 103.8 (29.3) | 0.004 | <0.0001 |
| HbA1c (%)          | 5.6 (0.6) | 5.6 (0.6) | 5.5 (0.6) | 0.05 | 5.6 (0.9) | 5.6 (0.9) | 5.6 (0.9) | 0.09 | <0.0001 |
| Systolic blood pressure (mm Hg) | 115.2 (17.5) | 115.6 (15.1) | 114.9 (19.1) | 0.03 | 122.1 (17.6) | 123.4 (16.4) | 121.0 (18.5) | <0.0001 | <0.0001 |
| Diastolic blood pressure (mm Hg) | 70.6 (9.8) | 72.1 (9.8) | 69.5 (9.7) | <0.0001 | 68.9 (12.4) | 69.9 (12.8) | 67.9 (12.0) | 0.0001 | <0.0001 |
| Total cholesterol (mg/dL) | 210.7 (51.1) | 205.9 (46.0) | 214.2 (54.3) | <0.0001 | 188.1 (43.3) | 181.8 (40.8) | 193.9 (44.8) | <0.0001 | <0.0001 |
| LDL cholesterol (mg/dL) | 132.6 (46.6) | 134.9 (43.2) | 130.9 (48.9) | 0.09 | 109.2 (31.1) | 108.7 (32.8) | 103.8 (29.3) | 0.004 | <0.0001 |
| % diabetes (adj %§, adj %¶) | 3.3 (3.3, 3.2) | 3.5 (3.5, 3.3) | 3.1 (3.1, 3.1) | 0.81 | 13.2 (13.1, 12.9) | 14.2 (14.1, 13.8) | 12.2 (12.2, 12.0) | 0.04 | <0.0001 |
| % hypertension (adj %§, adj %¶) | 12.7 (12.7, 12.7) | 11.6 (11.6, 11.6) | 13.5 (13.5, 13.5) | <0.0001 | 37.8 (37.8, 37.4) | 37.4 (37.4, 36.9) | 38.3 (38.3, 37.9) | <0.0001 | <0.0001 |
| % high total cholesterol (adj %§, adj %¶) | 26.2 (26.2, 26.2) | 23.0 (23.0, 23.1) | 28.5 (28.5, 28.5) | <0.0001 | 35.7 (35.5, 35.6) | 35.5 (35.3, 35.3) | 35.9 (35.7, 35.8) | 0.348 | 0.0003 |
| % high LDL cholesterol (adj %§, adj %¶) | 25.3 (25.3, 25.2) | 26.4 (26.4, 26.5) | 24.4 (24.4, 24.3) | 0.645 | 35.5 (33.4, 33.3) | 37.5 (34.9, 34.7) | 33.8 (32.1, 32.1) | 0.009 | 0.0033 |

In the Amish, diabetes based on 3302 subjects. Hypertension, high LDL cholesterol and high cholesterol based on 5370, 5374, and 5374 subjects, respectively (see text). In NHANES, diabetes based on 2444 subjects. Hypertension, high LDL cholesterol, and high total cholesterol based on 2403, 2527, and 2231 subjects, respectively (see text).

*P value calculated by logistic regression for categorical outcome or linear regression for continuous outcome, adjusting for age and sex. P value for age, adjusted for sex only. Bold values denote statistical significance at level 0.05.

†P value for sex difference calculated by logistic regression for binary outcome or linear regression for continuous outcome, adjusting for age. P value for age, adjusted for sex only. Bold values denote statistical significance at level 0.05.

‡P values for differences between Amish and NHANES were unchanged from the values provided when additionally adjusted for body mass index, with the exception of % high total cholesterol (age- and sex-adjusted p=0.0003 changed to 0.002 with additional adjustment for BMI) and % high LDL cholesterol (age-adjusted and sex-adjusted p=0.0003 changed to 0.002 with additional adjustment for BMI).

§Prevalence adjusted for age and sex using Poisson regression.

¶Prevalence adjusted for age, sex, and BMI using Poisson regression.

APOB, apolipoprotein B gene; BMI, body mass index; HbA1c, glycated hemoglobin; LDL, low-density lipoprotein; NHANES, National Health and Nutrition Examination Survey.
18.4% vs 11.3% for LDL cholesterol), although lower in the Amish in the two older age categories (33.7% vs 40.8% and 31.6% vs 37.8% for total and LDL cholesterol, respectively, at ages 45–64 years, and 43.2% vs 63.1% and 40.3% vs 62.1% for total and LDL cholesterol, respectively, at ages 65+ years) (figure 2 and table 2). Overall, the age-adjusted and sex-adjusted prevalence of high total cholesterol was 26.2% and 35.7% in the Amish and NHANES, respectively (PRR: 0.87 (95% CI 0.80 to 0.94), p<0.0001) and the age-adjusted and sex-adjusted prevalence of high LDL cholesterol was 25.3% and 35.5% in the Amish and NHANES, respectively (PRR: 0.87 (95% CI 0.79 to 0.95), p=0.0016). After excluding Amish subjects with the APOB R3527Q mutation, the prevalence of high total and LDL cholesterol was lower in the Amish at all ages and the prevalence of high total cholesterol was 37% lower in the Amish than in NHANES (PRR: 0.63 (95% CI 0.57 to 0.70), p<0.0001) and the prevalence of high LDL cholesterol was 39% lower (PRR: 0.60 (95% CI 0.54 to 0.67), p<0.0001).

Since the Amish are significantly less likely to take physician-prescribed medications than NHANES and thus less likely to be diagnosed on the basis of medication use alone, we considered the possibility that the lower frequency of hypertension and hypercholesterolemia observed in the Amish might be an artifact of the diagnostic criteria for these conditions being less sensitive in the Amish. If this were true, then one might expect to see that among those without a diagnosis of hypertension or high cholesterol, mean SBP was 4.5 mm Hg lower in Amish than in NHANES (110.6±11.3 vs 115.0±10.6 mm Hg, age-adjusted and sex-adjusted p<0.0001), while mean DBP was slightly higher in Amish (69.0±8.4 vs 68.6±9.6, p=0.04). Similarly, among individuals without diabetes, mean fasting glucose was 13.4 mg/dL lower in Amish than in NHANES (83.9±8.8 vs 97.3±10.0 mg/dL, age-adjusted and sex-adjusted p<0.0001), although mean HbA1c was slightly higher in Amish (5.5±0.3 vs 5.4±0.4%, p<0.0001). In contrast, among individuals without a diagnosis of high total cholesterol, mean total cholesterol was 9.4 mg/dL lower in Amish than in NHANES (189.2±28.7 vs 179.8±31.4 mg/dL, p<0.0001). Similarly, Amish had mean LDL cholesterol levels that were 9.2 mg/dL higher (113.6±25.9 vs 104.4±27.4 mg/dL, p<0.0001).

Control and treatment

Among individuals meeting diagnostic criteria for diabetes, hypertension, or hypercholesterolemia, Amish are less likely to be aware of their disease compared with NHANES (figure 3). For example, 51.3% of Amish with hypertension are aware of their disease compared with 87.6% of NHANES (p<0.0001) and 38.3% of Amish with high total blood cholesterol are aware of their disease compared with 79.4% of NHANES (p<0.0001). Differential awareness of diabetes was much smaller, with 63.6% of Amish with diabetes aware of their disease compared with 71.7% of NHANES (p=0.17).

Among those ‘aware’ of their disease, Amish were also less likely to report that they were currently taking medications to treat their disease compared with NHANES. For example, 72.1% of Amish aware of their diabetes reported taking glucose-lowering medications compared with 84.7% of NHANES (p=0.30). Similarly, 62.3% of
Epidemiology/Health services research

Amish aware of their hypertension reported taking blood pressure-lowering medications compared with 96.4% of NHANES (p<0.0001), and 30.6% of Amish aware of their hypercholesterolemia reported taking cholesterol-lowering medications compared with 90.2% of NHANES (p<0.0001).

Among subjects diagnosed with diabetes the proportion of Amish and NHANES achieving treatment targets for HbA1c (<7%) were comparable (49.1% vs 55.2%; age-adjusted and sex-adjusted PRR=0.89; 95% CI 0.66 to 1.21; p=0.56). In contrast, only 12.2% of Amish with hypertension achieved treatment targets for blood pressure control (target of SBP <130 mm Hg or DBP <80 mm Hg) compared with 39.5% for NHANES (age-adjusted and sex-adjusted PRR=0.31; 95% CI 0.24 to 0.39; p<0.0001) and only 1.2% of Amish with high total cholesterol achieved the <150 mg/dL treatment target for cholesterol compared with 16.9% for NHANES (age-adjusted and sex-adjusted PRR=0.15; 95% CI 0.09 to 0.23; p<0.0001). The proportion of subjects with high LDL achieving the LDL treatment target of <130 mg/dL was 8.8% in Amish compared with 64.0% in NHANES (age-adjusted and sex-adjusted PRR=0.20; 95% CI 0.16 to 0.25; p<0.0001).

DISCUSSION

We have shown that Amish have a lower prevalence of diabetes, hypertension, and hypercholesterolemia compared with non-Amish Caucasians. The magnitudes of the differences in disease rates between the two populations are striking, that is, a 66% lower prevalence of diabetes, 54% lower prevalence of hypertension, and a 13% lower prevalence of high total cholesterol. There is no evidence that the decreased prevalence of hypertension in the Amish is an artifact of NHANES with subthreshold levels of blood pressure being more likely than Amish to be treated with blood pressure lowering medications since SBP among non-hypertensive individuals is on average higher, not lower, in NHANES. However, among individuals not meeting diagnostic criteria for high cholesterol, cholesterol levels are on average slightly higher (by ~9 mg/dL) in Amish than in NHANES. We cannot therefore rule out the possibility that some of the difference in hypercholesterolemia prevalence rates might be due to non-Amish being more likely than Amish to have cholesterol levels in the high normal range and therefore more likely to be prescribed cholesterol-lowering medications.

Despite the lower frequency of diabetes, hypertension, and hypercholesterolemia in the Amish, these disorders still constitute significant public health problems in this community because of their associations with adverse events. This is especially true since Amish individuals with these disorders are less likely than NHANES to be aware that they are affected and less likely to be treated. Amish diagnosed with hypertension and high cholesterol are also less likely than NHANES to meet target treatment
guidelines. These results might be expected given that Amish do not participate in government-sponsored medical insurance programs and are less likely to receive medical care compared with non-Amish Caucasians in the USA.

The lower prevalence of hypercholesterolemia in the Amish occurs despite the fact that 12% of Amish carry at least one copy of a familial hypercholesterolemia-associated allele at the APOB locus that is associated with a ~70 mg/dL increase in LDL cholesterol levels. Moreover, if individuals with the APOB R3527Q mutation, a highly drifted variant associated with familial hypercholesterolemia carried by 12% of the Amish population, are excluded, Amish have a 37% lower prevalence of high total cholesterol. The Amish are also enriched for at least one other known genetic variant (near the pseudogene, APOOP1) that is also associated with high LDL cholesterol levels, with 15% of Amish carrying at least one copy of this variant and each copy associated with ~15 mg/dL increase in LDL cholesterol. Because of these mutations, the prevalence of high cholesterol is actually higher in younger Amish than in younger non-Amish, but as other (non-genetic) causes of high cholesterol become more prominent with age, the prevalence of high cholesterol becomes higher in the non-Amish beginning in middle age.

It seems likely that there are distinctive features about the Amish community or Amish lifestyle that contribute to their relative protection against diabetes, hypertension, and high cholesterol. Two features in particular stand

Figure 2  Prevalence of high total cholesterol and high LDL cholesterol in Amish and NHANES by age group. See text for diagnostic criteria. APOB, apolipoprotein B gene; LDL, low-density lipoprotein; NHANES, National Health and Nutrition Examination Survey.

Figure 3  Proportion of individuals with diabetes, hypertension, and high total cholesterol disease who are aware of their diagnosis, and among those aware, the proportion who are treated. NHANES, National Health and Nutrition Examination Survey.
out. First, the Amish tend to be far more physically active than their non-Amish counterparts, as we\textsuperscript{14} and others\textsuperscript{15,16} have previously documented. The protective effects of physical activity on cardiometabolic health are well documented, including in the Amish,\textsuperscript{17} and the more active Amish lifestyle may contribute to less diabetes, hypertension, and high cholesterol in this population. Second, the structure of Amish culture is very different from the non-Amish, and some aspects of this culture may confer additional benefits to cardiometabolic health. For example, Amish culture is very socially cohesive and at its core lies a strong ethos of community and family support. One can imagine that such a culture could be beneficial for dealing with stress. It is also possible that components of the Amish diet confer protection against these common cardiovascular risk factors. In sum, the relation of Amish culture to health is undoubtedly complex, and this is a topic in need of future study.

An intriguing observation from our study is that Amish have substantially lower fasting glucose levels compared with NHANES despite slightly higher levels of HbA1c. We have no clear explanation for this, and it is unlikely to be due to assay issues because glucose and HbA1c were measured in a central standardized lab (Quest). Possibly, glycemic excursions are not well captured in the Amish by a single fasting glucose. Amish do have slightly longer fasting times compared with NHANES, although this alone accounts for very little of the discrepancy. Amish, who tend to wake up early, may also be more physically active during the fasting period compared with non-Amish potentially contributing further to lower fasting glucose levels. It is also possible that non-glycemic factors (eg, red cell turnover and overall physical activity levels) may be at play that contribute to low fasting glucose levels in the Amish or to a mismatch of glucose and HbA1c levels.

One limitation of our study is that it is based on cross-sectional data. The possibility must therefore be considered that the incidence of one or more of these disorders could be similar between Amish and NHANES but Amish with these conditions might experience reduced survival, thus resulting in a lower prevalence. In fact, we have previously documented that Amish in general have less access to medical care.\textsuperscript{18} Although we are aware of no data specifically addressing case fatality from these conditions in the Amish, we regard this possibility as unlikely since overall mortality among Amish adults is very similar to that observed in the Framingham Heart Study Cohort, although this prior analysis was restricted to individuals born between 1890 and 1921.\textsuperscript{19} Our survey is based on a sample of the Amish community, and the frequencies of these disorders in this sample may not represent those in the overall community.

In summary, we have demonstrated that Amish have a substantially lower prevalence of diabetes and hypertension compared with NHANES and a moderately lower prevalence of high cholesterol. The reasons for these prevalence differences are not known although likely relate to distinctive features of the Amish lifestyle and community that may be protective for cardiometabolic health, such as the relative high levels of physical activity and the cohesive and supportive structure of the Amish community.

Acknowledgements The authors would like to acknowledge the substantial contributions of other staff members at the Amish Research Clinic, including Elizabeth Zehr, Tracy Broderick, Grace Redcay, Fred Young, Regina Guaraldi, Mary Morrissey, Theresa Roomet, and Mary McLane, as well as the many Amish liaisons who have contributed to these studies (Sarah Fisher, Sadie Fisher, Katie Stoltzfus, Mary Esh, Anna Esh, Naomi Esh, Susie Fisher, Hanna King, Sylvia King, Verna Petersheim, Barbie A Stoltzfus, Barbie B Stoltzfus, Fannie Stoltzfus, Mary Stoltzfus, Lydia Zook, and Esther Smucker).

Contributors Conceived and drafted the paper: SH and BDM; analyzed and interpreted data and drafted the manuscript: SH and KAR; data collection: MeD, DT, YR, PD, MaD, SN, SS and NW; commented on the drafts of the paper: KAR, EAS, PFM, ARS and TP; all authors have approved the final version for submission.

Funding This work was supported in part by National Institutes of Health grant P30 DK072488, the Regeneron Genetics Center, and the University of Maryland School of Medicine Program for Personalized and Genomic Medicine.

Competing interests ARS is an employee of Regeneron Pharmaceuticals, Inc and receives compensation.

Patient consent for publication Not required.

Ethics approval This study was approved by the Institutional Review Board at the University of Maryland, Baltimore (University of Maryland, Baltimore IRB HP-00043451).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. Data may be obtained from a third party and are not publicly available. Some unidentified Amish data are available on dbGaP (dbGaP Study Accession: phs000956.v3.p1). Further inquiries may be directed to the communicating author. National Health and Nutrition Examination Survey (NHANES) data are available through NHANES.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Braxton D Mitchell http://orcid.org/0000-0003-4920-4744

REFERENCES
1 Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke Statistics-2018 update: a report from the American heart association. \textit{Circulation} 2018;137:e67–492.
2 Danaei G, Ding EL, Mozaffarian D, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. \textit{PloS Med} 2009;6:e1000058.
3 Egan BM, Zhao Y, Axon RN. Us trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. \textit{JAMA} 2010;302:2043–50.
4 Egan BM, Li J, Hutchison FN, et al. Hypertension in the United States, 1999 to 2012: progress toward healthy people 2020 goals. \textit{Circulation} 2014;130:1692–9.
5 Menke A, Casagrande S, Geiss L, et al. Prevalence of and trends in diabetes among adults in the United States, 1988-2012. \textit{JAMA} 2015;314:1021–9.
6 Carroll MD, Kit BK, Lacher DA, et al. Trends in lipids and lipoproteins in US adults, 1988-2010. \textit{JAMA} 2012;308:1545–54.
7 Carroll MD, Fryar CD, Kit BK. Total and high-density lipoprotein cholesterol in adults: United States, 2011-2014. \textit{NCHS Data Brief} 2015;226:1–8.
8 Gu Q, Poulouse-Ram R, Burt VL, et al. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012. \textit{NCHS Data Brief} 2014;1:1–8.
9 Adefabag AS, Luepker RV, Roger VL, et al. Sudden cardiac death: epidemiology and risk factors. \textit{Nat Rev Cardiol} 2010;7:216–25.
10 Pollin TI, McBride DJ, Agarwala R, et al. Investigations of the Y chromosome, male founder structure and YSTR mutation rates in the old order Amish. *Hum Hered* 2008;65:91–104.

11 Shen H, Damcott CM, Rampersaud E, et al. Familial defective apolipoprotein B-100 and increased low-density lipoprotein cholesterol and coronary artery calcification in the old order Amish. *Arch Intern Med* 2010;170:1850–5.

12 Hsueh WC, Mitchell BD, Aburomia R, et al. Diabetes in the old order Amish: characterization and heritability analysis of the Amish family diabetes study. *Diabetes Care* 2000;23:595–601.

13 Montasser ME, O’Hare EA, Wang X, et al. An APO0 pseudogene on chromosome 5q is associated with LDL-C levels. *Circulation* 2018;138:1343–55.

14 Hairston KG, Ducharme JL, Treuth MS, et al. Comparison of BMI and physical activity between old order Amish children and non-Amish children. *Diabetes Care* 2013;36:873–8.

15 Bassett DR, Schneider PL, Huntington GE. Physical activity in an old order Amish community. *Med Sci Sports Exerc* 2004;36:79–85.

16 Bassett DR, Tremblay MS, Esliger DW, et al. Physical activity and body mass index of children in an old order Amish community. *Med Sci Sports Exerc* 2007;39:410–5.

17 Mitchell BD, Kalra G, Ryan KA, et al. Increased usual physical activity is associated with a blunting of the triglyceride response to a high-fat meal. *J Clin Lipidol* 2019;13:109–14.

18 Mitchell BD, Lee W-J, Tolea MI, et al. Living the good life? mortality and hospital utilization patterns in the old order Amish. *PLoS One* 2012;7:e51560.